Abstract: The present disclosure is directed to method for the generation and use of regulatory T cells (Tregs) in the prevention and treatment of graft/transplant rejection. In particular, the method employs engineered CAR Treg cells that protect transplanted materials from rejection.

Abstract: An expandable vertebral body device, system, instrument, and methods of assembly and using the device, system, and instrument are disclosed. The vertebral body device includes a body with a first end and a second end, a first rotating member rotatably coupled to the first end, a second rotating member rotatably coupled to the second end, a first extension member moveably coupled to the first end, and a second extension member moveably coupled to the second end. The expandable cage system comprises a vertebral body device and an insertion instrument. Methods for assembling and using the vertebral body device and instrument are also disclosed.

Abstract: The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Abstract: A stent graft system includes a primary body having a proximal end, a distal end, a first tubular graft material and multiple stents attached to the first tubular graft material. A first branch has a second tubular graft material forming a first branch lumen. The first branch traverses a first fenestration configured in the primary body with a first wire loaded therethrough. A second branch has a third tubular graft material and a second branch lumen. The second branch traverses a second fenestration configured in the primary body with a second wire loaded therethrough. A third branch has a fourth tubular graft material and a third branch lumen. The third branch traverses a third fenestration configured in the primary body with a third wire loaded therethrough. A method for placing a stent graft system is also described.

Abstract: The present disclosure provides biomarker panels for evaluating subjects at risk of sinusoidal obstruction syndrome (SOS) early after hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure relates to the use of ST2. L-Ficolin, and HA for prognosing, diagnosing, and/or treating SOS.

Abstract: The present invention provides minimally invasive subdural evacuating systems and methods of use thereof. The subdural evacuating systems include a cutting component and a rod component, wherein the rod component provides an external physical indicator that the surface of the dura mater has been reached, permitting the cutting component to accurately pierce the dura mater with minimal to no risk of damaging any adjacent anatomy.

Abstract: The present invention relates to compositions comprising induced T regulatory cells (iTregs), methods of making the compositions, and methods of using the compositions for enhancing bone remodeling in the treatment of Osteogenesis Imperfecta (OI).

Abstract: Provided herein are methods for the production of activated CD26high T cells by co-stimulation with inducible coactivator (ICOS). Further provided are methods for treatment of cancer by administration of the of activated CD26high T cells as an adoptive T cell therapy.

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.

Abstract: The presently disclosed subject matter relates to isolated compositions and methods for treating and/or preventing sepsis and inflammatory conditions, such as Acute Respiratory Distress Syndrome (ARDS). In some embodiments, the presently disclosed subject matter relates to endothelial progenitor cell-derived exosomes to treat and/or prevent sepsis and inflammatory conditions, such as Acute Respiratory Distress Syndrome (ARDS). The endothelial progenitor cell-derived exosomes can be modified to overexpress one or more miRNAs.

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.

Abstract: The present disclosure is directed to antibodies binding to AGR2 and cancer cells that express or overexpress AGR2, and methods for use thereof.

Abstract: The present invention provides expandable devices and insertion tools for deploying the expandable devices. The expandable devices are capable of increasing in height and width when expanded from a closed configuration to an open configuration to occupy a larger volume and to present a larger surface area. The expandable devices are lockable and are capable of rigidly occupying a space after expansion. In some embodiments, the expandable devices are useful as interbody devices for spinal fusions.

Abstract: Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.

Abstract: Compounds and methods are provided for the treatment of neurological or mitochondrial diseases, including epilepsy. In some embodiments, the compounds are substituted 1,4-naphthoquinones.

Abstract: The present disclosure provides methods of producing hybrid Th1/Th17 cells. Also provided herein are methods of treating cancer comprising targeting the CD38-mediated metabolic axis.

Abstract: The present disclosure is directed to method of diagnosing and treating heart disease using antibodies that bind to Cofilin, A? and/or Tau.

Abstract: The invention relates to KDM4B inhibitors, compositions comprising an effective amount of KDM4B inhibitors and methods for treating inflammatory diseases and disorders.

Abstract: A method comprising collecting magnetic resonance imaging (MRI) scanner data corresponding to a region of interest, establishing a spectral peak profile associated with at least one metabolite in the region of interest, wherein the spectral peak profile comprises a term in the FID vector signal included in the collected MRI scanner data, selecting at least three counter indices and corresponding points on the spectral peak profile to compute a linear fractional transformation (LFT), computing an N-dimensional vector outlining a spectral circle in a complex plane by applying the LFT to each counter index included in a set of equally-spaced counter indices associated with a three-dimensional spectrum representation of the collected MRI scanner data, shifting the spectral circle to eliminate a baseline offset for a magnitude spectrum associated with the complex plane, rotating the shifted spectral circle to produce a rotated spectral circle.

Abstract: A declogging assembly (20) is configured for use with a suction conduit (10). The suction conduit has a head (14) at a first end (15) and a vacuum tube connection (16) at a second end (17). The assembly includes a body (30). The body defines a first aperture (32), a second aperture (34), and a third aperture (36). The assembly also includes a plug (40) disposed within the body (30). The plug has a surface (42) configured to contact the head (14) of the suction conduit (10) so as to move the plug from a first position, in which the first aperture (32) is in fluid communication with the second aperture (34), to a second position, in which the first aperture (32) is in fluid communication with the third aperture (36). The assembly (20) also includes a biasing member (50) configured to bias the plug into the first position.